Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $10 from $19 and keeps a Buy rating on the shares. The Phase 1/2 study Cohort 1 results of ENTR-601-44 in DMD44 patients produced “lackluster dystrophin expression,” says the analyst, who looks forward to Cohort 2 results expected by year-end but is “unsure” whether Cohort 2 data would outperform Novartis’ (NVS) Del-zota.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study
- Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
- Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)
- Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data